The study analyzed that the prostatitis therapeutics pipeline comprises 11 drug candidates in different stages of development.
According to the research findings, one drug candidate has entered the Phase III stage of development in prostatitis therapeutics pipeline.
The drug candidates of prostatitis pipeline are in different stages of development. Among them, majority of drugs are being developed to be administered by oral route. For instance, Prulifloxacin, a Phase II drug candidate by Angelini Acraf SpA, is being developed to be administered by oral route. Oral route increases the patient compliance as it does not require the assistance of other healthcare professionals. It is the prodrug of ulifloxacin a broad-spectrum fluoroquinolone antibacterial agent that blocks the type II DNA topoisomerase.
Some of the key players developing drugs for the treatment of prostatitis therapeutics include Angelini Acraf SpA, TFPharma, and Aquinox Pharmaceuticals, Inc.
Report Segmentation
- By Phase
- By Molecule Type
- By Route of Administration
- By Company
Key Topics Covered:
Chapter 1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.4 Key Stakeholders
Chapter 2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
Chapter 3. Executive Summary
Chapter 4. Pipeline Outlook
4.1 Overview
4.2 Key Drivers
4.3 Key Barriers
4.4 Prostatitis Therapeutics Pipeline Analysis
Chapter 5. Prostatitis Therapeutics Pipeline Analysis by Phase (2017)
5.1 Phase III: Drug profiles
5.2 Phase II: Drug profiles
5.4 Discontinued: Drug Candidates
5.5 Inactive: Drug Candidates
Chapter 6. Clinical Trials Analysis
6.1 Clinical Trials by Region for Prostatitis Therapeutics Pipeline
6.2 Clinical Trials by Trial Status for Prostatitis Therapeutics Pipeline
GOT NEWS? click here
Google News, Bing News, Yahoo News, 200+ publications
Chapter 7. Competitive Landscape
7.1 Key Players Benchmarking for Prostatitis Therapeutics Pipeline
Chapter 8. Company Profiles
8.1 Business Overview
8.2 Product and Service Offerings
For more information about this report visit https://www.researchandmarkets.com/research/ttdqqj/global?w=5
Media Contact:
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:http://www.prnewswire.com/news-releases/global-prostatitis-therapeutics-pipeline-analysis-report-2017-by-phase-molecule-type-route-of-administration-and-company-300627127.html
SOURCE Research and Markets
Related Links
http://www.researchandmarkets.com